Search results for "Digestive System"

showing 10 items of 1747 documents

Galactosylated polymeric carriers for liver targeting of sorafenib

2014

In this paper, we describe the preparation of liver-targeted polymeric micelles potentially able to carry sorafenib to hepatocytes for treatment of hepatocarcinoma (HCC), exploiting the presence of carbohydrate receptors, ASGPR. These micelles were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. This latter was obtained by chemical reaction of α,β-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-d,l-aspartamide (PHEA-EDA) with polylactic acid (PLA), and subsequent reaction with lactose, leading to PHEA-EDA-PLA-GAL copolymer. Liver-targeted sorafenib-loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration value with nanometer …

NiacinamideSorafenibBiodistributionPolyestersBiological AvailabilityPharmaceutical ScienceAntineoplastic AgentsPharmacologyKidneyMicellechemistry.chemical_compoundPolylactic acidHepatic cell-targeted carriersmedicineZeta potentialAnimalsLungneoplasmsMicellesDrug CarriersActive targetingPhenylurea CompoundsHepatic cell-targeted carrierGalactoseActive targeting; Galactosylation; Hepatic cell-targeted carriers; Polymeric micellesSorafenibEthylenediaminesdigestive system diseasesMice Inbred C57BLLiverBiochemistrychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoGalactosylationDrug deliveryPolymeric micellesFemalePeptidesDrug carrierSpleenmedicine.drugConjugateInternational Journal of Pharmaceutics
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Novel inhibitors in development for hepatocellular carcinoma

2010

The multikinase inhibitor sorafenib was the first agent to demonstrate a survival benefit for patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Although sorafenib represents a landmark in the treatment of HCC and proved molecularly targeted therapy to be effective in this disease, it represents just the first step towards an improvement in systemic therapy. Since then, novel inhibitors have been evaluated in early clinical trials, showing potential activity.This article aims to review novel inhibitors emerging in the field of advanced HCC. An Internet-based search was performed to identify abstracts, clinical trials ( www.clinicaltrials.gov , last accessed 30 Nove…

NiacinamideSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularPyridinesmedicine.medical_treatmentMEDLINEAntineoplastic AgentsDiseasePharmacologySystemic therapyTargeted therapyDrug Delivery SystemsInternal medicinemedicineCarcinomaAnimalsHumansPharmacology (medical)PharmacologyClinical Trials as Topicbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDrugs InvestigationalGeneral MedicineSorafenibmedicine.diseasedigestive system diseasesClinical trialDrug DesignHepatocellular carcinomabusinessSignal Transductionmedicine.drugExpert Opinion on Investigational Drugs
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2014

Abstract: The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis. Even though patients with chronic liver diseases undergo clinical surveillance for early diagnosis of HCC, this cancer is often diagnosed in advanced stage. In this case locoregional treatment is not possible and systemic therapies are the best way to control it. Until now sorafenib, a Raf and multi-kinase inhibitor has been the best, choice to treat HCC systemically. It showed a survival benefit in multicenter phase III trials. However the proper patient setting to treat is not well defined, since the results in Child-Pugh B patients a…

NiacinamideVascular Endothelial Growth Factor ACarcinoma HepatocellularSettore MED/06 - Oncologia MedicaCirrhosis hepatocellular carcinoma liver disease targeted therapiesAntineoplastic AgentsBiochemistryDrug DiscoveryAnimalsHumansMolecular Targeted TherapyBiologyProtein Kinase InhibitorsPharmacologyPharmacology. TherapyPhenylurea CompoundsTOR Serine-Threonine KinasesLiver NeoplasmsOrganic ChemistryAntibodies MonoclonalSorafenibdigestive system diseasesErbB ReceptorsChemistryLiverMolecular MedicineCurrent Medicinal Chemistry
researchProduct

Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity

2006

Abstract Plasmids pQE-60 and pQE-30 containing 6× His-tag sequence were used for expression of fragments of HCV structural and non-structural proteins in Escherichia coli (E. coli). The following fragments were used: core (1–98 aa), NS3 (202–482 aa), and tetramer of hypervariable region 1 (HVR1) of E2 protein. The constructed plasmids directed high levels of expression of HCV proteins in E. coli JM109. After purification by the metal-affinity chromatography on nickel–nitrilotriacetic acid (Ni–NTA) agarose, the His-tagged HCV proteins were used for immunization of BALB/c mice. All three proteins were able to induce high levels of specific antibodies and, in the case of the NS3 and HVR1 tetra…

Nitrilotriacetic AcidHepatitis C virusDose-Response Relationship ImmunologicViral Nonstructural ProteinsBiologymedicine.disease_causeSensitivity and SpecificityChromatography AffinityAntigen-Antibody ReactionsMiceViral Proteinschemistry.chemical_compoundPlasmidTetramerNickelmedicineAnimalsCloning MolecularEscherichia coliCell ProliferationMice Inbred BALB CNS3Viral Core ProteinsImmunogenicityvirus diseasesHepatitis C AntibodiesVirologyMolecular biologyPeptide FragmentsRecombinant Proteinsdigestive system diseasesHypervariable regionchemistryAgaroseFemaleImmunizationHepatitis C AntigensPeptidesSpleenBiotechnologyProtein Expression and Purification
researchProduct

Transplanting the genetic susceptibility to Crohn’s disease

2003

Susceptibility to Crohn’s disease may be transferred via haematopoietic stem cells, highlighting the pivotal role of genetic factors in the pathogenesis of Crohn’s disease Crohn’s disease (CD) is one of the two most common forms of inflammatory bowel disease (IBD). The prevalence of CD has increased in Western countries over the past decades and mainly young patients are affected, with a peak incidence between 15 and 35 years.1 The aetiology of IBD is still unclear and should be considered as multifactorial according to recent studies.2 Genetic factors seem to play a pathogenic role as well as environmental, infectious, and immunological factors. All of these different aetiological aspects …

Nod2 Signaling Adaptor ProteinCase ReportBiologyInflammatory bowel diseaseProinflammatory cytokinePathogenesisImmune systemCrohn DiseasemedicineGenetic predispositionHumansGenetic Predisposition to DiseaseCrohn's diseasePolymorphism GeneticGastroenterologyIntracellular Signaling Peptides and ProteinsT helper cellT-Lymphocytes Helper-Inducermedicine.diseaseHodgkin Diseasedigestive system diseasesmedicine.anatomical_structureImmunologyCommentaryStem cell5' Untranslated RegionsCarrier ProteinsStem Cell Transplantation
researchProduct

Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity.

2012

Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity

Non-Celiac Wheat SensitivityPediatricsmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologybusiness.industryNon-celiac gluten sensitivityGastroenterologyDouble-Blind Placebo-Controlled Challengenutritional and metabolic diseasesfood and beveragesmedicine.diseasePlaceboFood hypersensitivitydigestive system diseasesDouble blindNon-Celiac Wheat Sensitivity; Double-Blind Placebo-Controlled Challenge;Severity of illnessmedicineDifferential diagnosisbusinessNon-celiac gluten sensitivityIrritable bowel syndromeWheat allergy
researchProduct

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?

2020

Nonalcoholic steatohepatitismedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryMEDLINEMagnetic resonance imagingClinical trialEditorialText miningmedicinelcsh:Diseases of the digestive system. GastroenterologyRadiologylcsh:RC799-869businessHepatology Communications
researchProduct

Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report.

1999

A case of a 62-year-old patient with hereditary hemochromatosis is reported, who developed hepatocellular carcinoma (HCC) in the absence of cirrhosis and other potential risk factors for HCC. Occurrence of HCC in patients with genetic hemochromatosis and noncirrhotic liver is a rare event which has previously been described only six times and appears to be limited to male patients.

Noncirrhotic liverMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularIronGenetic hemochromatosisHemosiderinGastroenterologyPathology and Forensic MedicineHLA AntigensInternal medicineCarcinomamedicineHumansIn patientHemochromatosis ProteinneoplasmsPotential riskbusiness.industryHistocompatibility Antigens Class ILiver NeoplasmsMembrane ProteinsCell BiologyMiddle Agedmedicine.diseasedigestive system diseasesHepatocellular carcinomaHereditary hemochromatosisHemochromatosisbusinessPathology, research and practice
researchProduct

An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.

2005

Summary Background : Alginate-based preparations act as mechanical antireflux barrier, which can reduce both acid and non-acid reflux events and limit the proximal migration of oesophageal refluxate. Aim : To evaluate all the above features with a novel technique, multichannel electrical impedance and pH-metry. Methods : Ten reflux patients underwent stationary impedancemetry and pH-metry after eating a refluxogenic meal. They were studied 1 h in basal conditions and 1 h after taking 10 mL of Gaviscon Advance. In both sessions, measurements were obtained in right lateral and supine decubitus. Results : Alginate preparation was able to decrease significantly (P < 0.05) the number of acid ref…

Novel techniqueAdultMalemedicine.medical_specialtySYMPTOMATIC TREATMENTACID REFLUXAlginatesSymptomatic treatmentSilicic AcidUrologySupine decubitusGASTROESOPHAGEAL-REFLUX DISEASEAluminum HydroxideGastric AcidPh metrymedicineHumansPharmacology (medical)Sodium alginateGASTROESOPHAGEAL-REFLUX DISEASE; SYMPTOMATIC TREATMENT; ACID REFLUXAgedHepatologybusiness.industrydigestive oral and skin physiologyGastroenterologyRefluxHydrogen-Ion ConcentrationMiddle Ageddigestive system diseasesSurgeryClinical PracticeDrug CombinationsSodium BicarbonateGastroesophageal RefluxDrug EvaluationFemaleAntacidsbusinessAlimentary pharmacologytherapeutics
researchProduct